Ignite Creation Date:
2024-05-06 @ 5:20 PM
Last Modification Date:
2024-10-26 @ 2:26 PM
Study NCT ID:
NCT05271318
Status:
RECRUITING
Last Update Posted:
2024-05-23
First Post:
2022-02-04
Brief Title:
Oncolytic Adenovirus Coding for TNFa and IL2 TILT-123 With Pembrolizumab or Pembrolizumab and Pegylated Liposomal Doxorubicin as Treatment for Ovarian Cancer
Sponsor:
TILT Biotherapeutics Ltd
Organization:
TILT Biotherapeutics Ltd
Organization Data
Organization:
TILT Biotherapeutics Ltd
Class:
INDUSTRY
Study ID:
TILT-T563
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
TILT Biotherapeutics Ltd
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Merck Sharp Dohme LLC | INDUSTRY |